Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options

Bibliography

• Dunsmuir WD, Kirby RS. Francois de LaPeyronie (1978 – 1747): the man and the disease he described. Br J Urol 1996;78:613-22
   PubMedGoogle Scholar
• Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie's disease. Drugs 2007;67:527-45
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ. Medical management of Peyronie's disease. J Androl 2009;30:397-405
   PubMed Web of Science ®Google Scholar
• Muller A, Mulhall JP. Peyronie's disease intervention trials: methodological challenges and issues. J Sex Med 2009;6:848-61
   PubMedGoogle Scholar
• Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9
   PubMed Web of Science ®Google Scholar
• Gholami SS, Gonzalez-Cadavid NF, Lin CS, Peyronie's disease: a review. J Urol 2003;169:1234-41
   PubMed Web of Science ®Google Scholar
• Bella AJ, Perelman MA, Brant WO. Lue TF. Peyronie's disease (CME). J Sex Med 2007;4:1527-38
   PubMed Web of Science ®Google Scholar
• Lin CS, Lin G, Wang Z, Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Biochem Biophys Res Commun 2002;295:1014-19
   PubMedGoogle Scholar
• Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005;2:291-7
   PubMedGoogle Scholar
• Fornara P, Gerbershagen HP. Ultrasound in patients affected with Peyronie's disease. World J Urol 2004;22:365-7
   PubMed Web of Science ®Google Scholar
• Bekos A, Arvaniti M, Hatzimouratidis K, The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol 2008;53:644-50
   PubMed Web of Science ®Google Scholar
• Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997;157:311-15
   PubMed Web of Science ®Google Scholar
• Greenfield JM, Levine LA. Peyronie's disease: etiology, epidemiology and medical treatment. Urol Clin North Am 2005;32:469-78
   PubMed Web of Science ®Google Scholar
• Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948;41:173-7
   PubMedGoogle Scholar
• Scardino PL, Kelley RA, Scott WW. Seminal tract tuberculosis: an evaluation of Young's radical operation for eradication of tuberculosis of the prostate, seminal vesicles, vasa and epididymides. J Urol 1950;63:698-711
   PubMedGoogle Scholar
• Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007;178:1398-403
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Hisasue S, Kato R, Outcome analysis for conservative management of Peyronie's disease. Int J Urol 2006;13:244-7
   PubMed Web of Science ®Google Scholar
• Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-6
   PubMed Web of Science ®Google Scholar
• Pryor J, Akkus E, Alter G, Peyronie's disease. J Sex Med 2004;1:110-15
   PubMed Web of Science ®Google Scholar
• Teloken C, Rhoden EL, Grazziotin TM, Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5
   PubMed Web of Science ®Google Scholar
• Akkus E, Carrier S, Rehman J, Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994;44:291-5
   PubMed Web of Science ®Google Scholar
• Lin G, Shindel AW, Banie L, Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010;7:1787-97
   PubMed Web of Science ®Google Scholar
• Valente EG, Vernet D, Ferrini MG, L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003;9:229-44
   PubMed Web of Science ®Google Scholar
• Takami M, Cho ES, Lee SY, Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 2005;579:832-8
   PubMedGoogle Scholar
• Ferrini MG, Kovanecz I, Nolazco G, Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006;97:625-33
   PubMed Web of Science ®Google Scholar
• Vernet D, Ferrini MG, Valente EG, Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002;7:262-76
   PubMed Web of Science ®Google Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994;151:1522-4
   PubMed Web of Science ®Google Scholar
• Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002;168:621-6
   PubMed Web of Science ®Google Scholar
• Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002;168:2483-5
   PubMed Web of Science ®Google Scholar
• Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C. [Iontophoresis in the conservative treatment of Peyronie's disease: preliminary experience]. Arch Ital Urol Androl 1997;69:323-7
   PubMedGoogle Scholar
• Cabello Benavente R, Moncada Iribarren I, de Palacio Espana A, Transdermal iontophoresis with dexamethasone and verapamil for Peyronie's disease. Actas Urol Esp 2005;29:955-60
   PubMedGoogle Scholar
• Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003;169:1775-8
   PubMed Web of Science ®Google Scholar
• Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006;49:987-97
   PubMedGoogle Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004;171:1605-8
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Cockerham YR. Intralesional injection therapy for Peyronie's disease. J Sex Med 2009;6:1811-14
   PubMedGoogle Scholar
• Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007;69:1181-4
   PubMed Web of Science ®Google Scholar
• Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol 2007;51:640-7
   PubMedGoogle Scholar
• Roth M, Eickelberg O, Kohler E, Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996;93:5478-82
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002;14:397-405
   PubMed Web of Science ®Google Scholar
• Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998;51:620-6
   PubMed Web of Science ®Google Scholar
• Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology 1983;21:584-5
   PubMedGoogle Scholar
• Lue TF, Giuliano F, Montorsi F, Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23
   PubMed Web of Science ®Google Scholar
• Kendirci M, Usta MF, Matern RV, The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005;2:709-15
   PubMed Web of Science ®Google Scholar
• Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997;79:40-2
   PubMedGoogle Scholar
• Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997;32:190-3
   PubMed Web of Science ®Google Scholar
• Duncan MR, Hasan A, Berman B. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol 1995;104:282-6
   PubMedGoogle Scholar
• Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991;25:89-94
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Kendirci M, Matern R, Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8
   PubMed Web of Science ®Google Scholar
• Hurst LC, Badalamente MA, Hentz VR, Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009;361:968-79
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982;10:135-40
   PubMed Web of Science ®Google Scholar
• Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993;149:56-8
   PubMed Web of Science ®Google Scholar
• Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008;5:180-7
   PubMed Web of Science ®Google Scholar
• Ehrlich HP. Scar contracture: cellular and connective tissue aspects in Peyronie's disease. J Urol 1997;157:316-19
   PubMed Web of Science ®Google Scholar
• Palmieri A, Imbimbo C, Longo N, A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009;56:363-9
   PubMed Web of Science ®Google Scholar
• Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie's disease. Urology 2002;60:795-800
   PubMedGoogle Scholar
• Hauck EW, Mueller UO, Bschleipfer T, Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol 2004;171:740-5
   PubMedGoogle Scholar
• Furlow WL, Swenson HE Jr, Lee RE. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975;114:69-71
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Branch J, Lubrano T, Shankey TV. Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. J Urol 2003;170:281-4
   PubMedGoogle Scholar
• Gontero P, Di Marco M, Giubilei G, Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009;6:558-66
   PubMed Web of Science ®Google Scholar
• Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med 2008;5:1468-73
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Sanli O, Akman T, Surgical treatment of Peyronie's disease: a single center experience with 145 patients. Eur Urol 2008;53:432-9
   PubMed Web of Science ®Google Scholar
• Kayigil O, Agras K, Aldemir M, Okulu E. The combination of vein grafting and two different types of corporeal plication in complex curvature due to Peyronie's disease. Urol Int 2010;84:275-81
   PubMedGoogle Scholar
• Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 1965;93:230-2
   PubMed Web of Science ®Google Scholar
• Chand N, Eyre P. Classification and biological distribution of histamine receptor sub-types. Agents Actions 1975;5:277-95
   PubMedGoogle Scholar
• Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie's disease. J Urol 1979;122:622-3
   PubMedGoogle Scholar
• Dugi DD III, Morey AF. Penoscrotal plication as a uniform approach to reconstruction of penile curvature. BJU Int 2010;105:1440-4
   PubMedGoogle Scholar
• Bokarica P, Parazajder J, Mazuran B, Gilja I. Surgical treatment of Peyronie's disease based on penile length and degree of curvature. Int J Impot Res 2005;17:170-4
   PubMed Web of Science ®Google Scholar
• Rolle L, Tamagnone A, Timpano M, The Nesbit operation for penile curvature: an easy and effective technical modification. J Urol 2005;173:171-4
   PubMed Web of Science ®Google Scholar
• Bella AJ, Beasley KA, Obied A, Brock GB. Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. Urology 2006;68:852-7
   PubMedGoogle Scholar
• Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol 2006;175:238-41
   PubMed Web of Science ®Google Scholar
• Moyano Calvo JL, Sanchez de la Vega J, Giraldez Puig J, Our experience with the Nesbit technique for the treatment of Peyronie's disease. Arch Esp Urol 2006;59:511-15
   PubMedGoogle Scholar
• Paez A, Mejias J, Vallejo J, Long-term patient satisfaction after surgical correction of penile curvature via tunical plication. Int Braz J Urol 2007;33:502-9
   PubMedGoogle Scholar
• Taylor FL, Levine LA. Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med 2008;5:2221-30
   PubMed Web of Science ®Google Scholar
• Ding S, Lu J, Zhang H, A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease. Int Urol Nephrol 2010;42(3):597-602
   PubMedGoogle Scholar
• Tornehl CK, Carson CC. Surgical alternatives for treating Peyronie's disease. BJU Int 2004;94:774-83
   PubMedGoogle Scholar
• Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 2002;167:2066-9
   PubMed Web of Science ®Google Scholar
• Simonato A, Gregori A, Varca V, Penile dermal flap in patients with Peyronie's disease: long-term results. J Urol 2010;183:1065-8
   PubMedGoogle Scholar
• Cormio L, Zucchi A, Lorusso F, Surgical treatment of Peyronie's disease by plaque incision and grafting with buccal mucosa. Eur Urol 2009;55:1469-75
   PubMed Web of Science ®Google Scholar
• Radopoulos D, Vakalopoulos I, Thanos P. Preputial graft in penile curvature correction: preliminary results. Int J Impot Res 2009;21:82-7
   PubMedGoogle Scholar
• Liu B, Zhu XW, Zhong DC, Replacement of plaque by buccal mucosa in the treatment of Peyronies disease: a report of 27 cases. Zhonghua Nan Ke Xue 2009;15:45-7
   PubMedGoogle Scholar
• Goyal NK, Kumar A, Das SK, Experience with plaque excision and dermal grafting in the surgical treatment of Peyronie's disease. Singapore Med J 2008;49:805-8
   PubMed Web of Science ®Google Scholar
• Breyer BN, Brant WO, Garcia MM, Complications of porcine small intestine submucosa graft for Peyronie's disease. J Urol 2007;177:589-91
   PubMedGoogle Scholar
• Hsu GL, Chen HS, Hsieh CH, Long-term results of autologous venous grafts for penile morphological reconstruction. J Androl 2007;28:186-93
   PubMedGoogle Scholar
• Knoll LD. Use of porcine small intestinal submucosal graft in the surgical management of tunical deficiencies with penile prosthetic surgery. Urology 2002;59:758-61
   PubMed Web of Science ®Google Scholar
• Knoll LD. Re: porcine small intestinal submucosa is not an ideal graft material for Peyronie's disease surgery. John T, Bandi G Santucci R, editors. J Urol 2006;176:1025-1029, J Urol 2007;177:1204
   PubMedGoogle Scholar
• Craatz S, Spanel-Borowski K, Begemann JF, The dorsal lamina of the rectus sheath: a suitable grafting material for the penile tunica albuginea in Peyronie's disease? BJU Int 2006;97:134-7
   PubMed Web of Science ®Google Scholar
• Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie's disease. BJU Int 2005;95:1029-33
   PubMed Web of Science ®Google Scholar
• Shioshvili TJ, Kakonashvili AP. The surgical treatment of Peyronie's disease: replacement of plaque by free autograft of buccal mucosa. Eur Urol 2005;48:129-5
   PubMed Web of Science ®Google Scholar
• Lahme S, Gotz T, Bichler KH. Collagen fleece for defect coverage following plaque excision in patients with Peyronie's disease. Eur Urol 2002;41:401-5
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Sanli O, Akman T, Graft materials in Peyronie's disease surgery: a comprehensive review. J Sex Med 2007;4:581-95
   PubMed Web of Science ®Google Scholar
• Ma LM, Jiang H, Zhou J, Snodgrass technique, Duckett repair and bladder mucosa grafting for hypospadias: an analysis of 251 cases. Zhonghua Nan Ke Xue 2009;15:1068-71
   PubMedGoogle Scholar
• Dublin N, Stewart LH. Oral complications after buccal mucosal graft harvest for urethroplasty. BJU Int 2004;94:867-9
   PubMedGoogle Scholar
• Santucci RA, Barber TD. Resorbable extracellular matrix grafts in urologic reconstruction. Int Braz J Urol 2005;31:192-203
   PubMedGoogle Scholar
• Sievert KD, Tanagho EA. Organ-specific acellular matrix for reconstruction of the urinary tract. World J Urol 2000;18:19-25
   PubMedGoogle Scholar
• John T, Bandi G, Santucci R. Porcine small intestinal submucosa is not an ideal graft material for Peyronie's disease surgery. J Urol 2006;176:1025-9
   PubMed Web of Science ®Google Scholar
• Fu Q, Cao YL. Use of tissue engineering in treatment of the male genitourinary tract abnormalities. J Sex Med 2010;7:1741-6
   PubMedGoogle Scholar
• Chaudhary M, Sheikh N, Asterling S, Peyronie's disease with erectile dysfunction: penile modeling over inflatable penile prostheses. Urology 2005;65:760-4
   PubMed Web of Science ®Google Scholar
• Henry GD, Wilson SK. Updates in inflatable penile prostheses. Urol Clin North Am 2007;34:535-47
   PubMed Web of Science ®Google Scholar
• Taylor FL, Levine LA. Peyronie's disease. Urol Clin North Am 2007;34:517-34
   PubMed Web of Science ®Google Scholar
• Ralph D, Gonzalez-Cadavid N, Mirone V, The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010;7:2359-74
   PubMed Web of Science ®Google Scholar
• Smith JF, Walsh TJ, Lue TF. Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res 2008;20:445-59
   PubMed Web of Science ®Google Scholar
• Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9
   PubMed Web of Science ®Google Scholar
• Grasso M, Lania C, Fortuna F, Preservation of cavernosal erectile function after soft penile prosthesis implant in Peyronie's disease: long-term followup [Article id: 646052]. Adv Urol 2008. [Epub 2 December 2008]
   Google Scholar
• Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002;14:406-10
   PubMed Web of Science ®Google Scholar
• El-Sakka AI, Hassoba HM, Pillarisetty RJ, Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997;158:1391-4
   PubMed Web of Science ®Google Scholar
• Haag SM, Hauck EW, Szardening-Kirchner C, Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007;51:255-61
   PubMedGoogle Scholar
• Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001;165:419-23
   PubMed Web of Science ®Google Scholar
• Vernet D, Nolazco G, Cantini L, Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod 2005;73:1199-210
   PubMed Web of Science ®Google Scholar
• Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J Sex Med 2009;6:1729-35
   PubMed Web of Science ®Google Scholar
• Agrawal V, Ellins E, Donald A, Systemic vascular endothelial dysfunction in Peyronie's disease. J Sex Med 2008;5:2688-93
   PubMedGoogle Scholar
• Ryu JK, Piao S, Shin HY, IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009;6:1284-96
   PubMed Web of Science ®Google Scholar
• Ding S, Lu J, Zhang H, A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease. Int Urol Nephrol 2010;42(3):597-602
   PubMedGoogle Scholar
• Austoni E, Colombo F, Romano AL, Soft prosthesis implant and relaxing albugineal incision with saphenous grafting for surgical therapy of Peyronie's disease: a 5-year experience and long-term follow-up on 145 operated patients. Eur Urol 2005;47(2):223-9; discussion 229. (PMID: 15661418)
   PubMedGoogle Scholar
• Knoll LD. Use of small intestinal submucosa graft for the surgical management of Peyronie's disease. J Urol 2007;178:2474-8; discussion 2478
   PubMedGoogle Scholar